{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T06:54:52Z","timestamp":1785740092361,"version":"3.56.0"},"reference-count":170,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K12810"],"award-info":[{"award-number":["JP24K12810"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"HOYA Corporation","award":["AT"],"award-info":[{"award-number":["AT"]}]},{"name":"AMO Japan, Inc.","award":["AT"],"award-info":[{"award-number":["AT"]}]},{"DOI":"10.13039\/501100004286","name":"Santen","doi-asserted-by":"publisher","award":["AT"],"award-info":[{"award-number":["AT"]}],"id":[{"id":"10.13039\/501100004286","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Refractory inflammatory ocular diseases\u2014uveitic macular edema (UME), acute retinal necrosis (ARN), and vitreoretinal lymphoma (VRL)\u2014pose significant diagnostic and therapeutic challenges due to their vision- or life-threatening nature and limited treatment options. UME, a leading cause of vision loss in intermediate, posterior, and panuveitis, affects approximately 40% of such cases, particularly in elderly patients and those with prolonged inflammation. Despite its prevalence, effective treatment is still being explored. ARN, caused by herpes viruses such as herpes simplex virus (HSV)-1, HSV-2, and varicella-zoster virus, ranks among the retinal diseases with the poorest visual prognosis; nearly half of patients experience a visual acuity (VA) of \u2264 0.1 within six months. However, a standardized treatment regimen has not yet been established. VRL, one of the ocular malignancies with the lowest overall survival rate, is frequently misdiagnosed as uveitis. Given the diagnostic delay and high frequency (60\u201385%) of central nervous system involvement\u2014which is often directly life-threatening\u2014early detection and comprehensive systemic management are essential. This review highlights recent advances in the diagnosis, clinical trials, and management of these three challenging ocular inflammatory diseases, emphasizing unmet needs and emerging therapeutic strategies.<\/jats:p>","DOI":"10.1007\/s10384-025-01310-3","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T03:01:28Z","timestamp":1765335688000},"page":"18-40","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Recent advances in the diagnosis and treatment of refractory ocular inflammatory diseases: focus on uveitic macular edema, acute retinal necrosis, and vitreoretinal lymphoma"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0806-6146","authenticated-orcid":false,"given":"Atsunobu","family":"Takeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyo","family":"Yawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koh-Hei","family":"Sonoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"1310_CR1","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/eye.2016.115","volume":"30","author":"C Fardeau","year":"2016","unstructured":"Fardeau C, Champion E, Massamba N, LeHoang P. Uveitic macular edema. Eye (Lond). 2016;30:1277\u201392.","journal-title":"Eye (Lond)"},{"key":"1310_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/09273948.2019.1576910","volume":"27","author":"M Accorinti","year":"2019","unstructured":"Accorinti M, Okada AA, Smith JR, Gilardi M. Epidemiology of macular edema in uveitis. Ocul Immunol Inflamm. 2019;27:169\u201380.","journal-title":"Ocul Immunol Inflamm"},{"key":"1310_CR3","doi-asserted-by":"crossref","unstructured":"Mustafi D, Do BK, Rodger DC, Rao NA. Relationship of epiretinal membrane formation and macular edema development in a large cohort of uveitic eyes. Ocul Immunol Inflamm. 2020;29:915\u2013921.","DOI":"10.1080\/09273948.2019.1704026"},{"key":"1310_CR4","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ajo.2020.06.038","volume":"219","author":"JH Kempen","year":"2020","unstructured":"Kempen JH, Van Natta ML, Friedman DS, Altaweel MM, Ansari H, Dunn JP, et al. Incidence and outcome of uveitic glaucoma in eyes with intermediate, posterior, or panuveitis followed up to 10 years after randomization to fluocinolone acetonide implant or systemic therapy. Am J Ophthalmol. 2020;219:303\u201316.","journal-title":"Am J Ophthalmol"},{"key":"1310_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ajo.2017.08.019","volume":"183","author":"YJ Sepah","year":"2017","unstructured":"Sepah YJ, Sadiq MA, Chu DS, Dacey M, Gallemore R, Dayani P, et al. Primary (month-6) outcomes of the stop-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol. 2017;183:71\u201380.","journal-title":"Am J Ophthalmol"},{"key":"1310_CR6","doi-asserted-by":"publisher","first-page":"152153","DOI":"10.1016\/j.semarthrit.2022.152153","volume":"58","author":"N Barroso-Garcia","year":"2023","unstructured":"Barroso-Garcia N, Atienza-Mateo B, Ferraz-Amaro I, Prieto-Pena D, Beltran E, Adan A, et al. Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet\u2019s disease. Multicenter study of 49 patients. Semin Arthritis Rheum. 2023;58:152153.","journal-title":"Semin Arthritis Rheum"},{"key":"1310_CR7","first-page":"607","volume":"25","author":"A Urayama","year":"1971","unstructured":"Urayama A, Yamada N, Sasaki T. Unilateral acute uveitis with retinal periarteritis and detachment. Rinsho Ganka. 1971;25:607\u201319 (in Japanese).","journal-title":"Rinsho Ganka"},{"key":"1310_CR8","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.ajo.2019.08.007","volume":"208","author":"M Hafidi","year":"2019","unstructured":"Hafidi M, Janin-Manificat H, Denis P, Charleux B, Rabilloud M, Boibieux A, et al. Acute retinal necrosis: virological features using quantitative polymerase chain reaction, therapeutic management, and clinical outcomes. Am J Ophthalmol. 2019;208:376\u201386.","journal-title":"Am J Ophthalmol"},{"key":"1310_CR9","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.oret.2022.01.016","volume":"6","author":"JC Bavinger","year":"2022","unstructured":"Bavinger JC, Anthony CL, Lindeke-Myers AT, Lynch S, Xu LT, Barnett J, et al. Risk factors for retinal detachment in acute retinal necrosis. Ophthalmol Retina. 2022;6:478\u201383.","journal-title":"Ophthalmol Retina"},{"key":"1310_CR10","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1038\/s41433-024-03028-x","volume":"38","author":"D Kalogeropoulos","year":"2024","unstructured":"Kalogeropoulos D, Afshar F, Kalogeropoulos C, Vartholomatos G, Lotery AJ. Diagnostic and therapeutic challenges in acute retinal necrosis; an update. Eye (Lond). 2024;38:1816\u201326.","journal-title":"Eye (Lond)"},{"key":"1310_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10384-012-0150-7","volume":"56","author":"K Kimura","year":"2012","unstructured":"Kimura K, Usui Y, Goto H, Japanese Intraocular Lymphoma Study G. Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. Jpn J Ophthalmol. 2012;56:383\u20139.","journal-title":"Jpn J Ophthalmol"},{"key":"1310_CR12","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00417-004-0973-0","volume":"242","author":"SE Coupland","year":"2004","unstructured":"Coupland SE, Heimann H, Bechrakis NE. Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefes Arch Clin Exp Ophthalmol. 2004;242:901\u201313.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1310_CR13","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.survophthal.2023.12.001","volume":"69","author":"RS Huang","year":"2024","unstructured":"Huang RS, Mihalache A, Popovic MM, Cruz-Pimentel M, Pandya BU, Muni RH, et al. Diagnostic methods for primary vitreoretinal lymphoma: a systematic review. Surv Ophthalmol. 2024;69:456\u201364.","journal-title":"Surv Ophthalmol"},{"key":"1310_CR14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF00163549","volume":"14","author":"RB Nussenblatt","year":"1990","unstructured":"Nussenblatt RB. The natural history of uveitis. Int Ophthalmol. 1990;14:303\u20138.","journal-title":"Int Ophthalmol"},{"key":"1310_CR15","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/bjo.80.4.332","volume":"80","author":"A Rothova","year":"1996","unstructured":"Rothova A, van Suttorp- Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332\u20136.","journal-title":"Br J Ophthalmol"},{"key":"1310_CR16","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.ophtha.2006.03.027","volume":"113","author":"CW Lardenoye","year":"2006","unstructured":"Lardenoye CW, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113:1446\u20139.","journal-title":"Ophthalmology"},{"key":"1310_CR17","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.3390\/jcm10184133","volume":"10","author":"SJ Teper","year":"2021","unstructured":"Teper SJ. Update on the management of uveitic macular edema. J Clin Med. 2021;10:4133.","journal-title":"J Clin Med"},{"key":"1310_CR18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/ICU.0b013e3282f03d2e","volume":"18","author":"A Rothova","year":"2007","unstructured":"Rothova A. Inflammatory cystoid macular edema. Curr Opin Ophthalmol. 2007;18:487\u201392.","journal-title":"Curr Opin Ophthalmol"},{"key":"1310_CR19","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/09273948.2017.1358377","volume":"27","author":"JH Lee","year":"2019","unstructured":"Lee JH, Mi H, Lim R, Ho SL, Lim WK, Teoh SC, et al. Ocular autoimmune systemic inflammatory infectious study - report 3: posterior and panuveitis. Ocul Immunol Inflamm. 2019;27:89\u201398.","journal-title":"Ocul Immunol Inflamm"},{"key":"1310_CR20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1080\/09273940701244509","volume":"15","author":"NN Markomichelakis","year":"2007","unstructured":"Markomichelakis NN, Halkiadakis I, Pantelia E, Georgalas I, Chrysanthi K, Theodossiadis P, et al. Course of macular edema in uveitis under medical treatment. Ocul Immunol Inflamm. 2007;15:71\u20139.","journal-title":"Ocul Immunol Inflamm"},{"key":"1310_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3109\/09273948.2013.871566","volume":"23","author":"J de Boer","year":"2015","unstructured":"de Boer J, Steijaert A, van den Bor R, Stellato R, van Ossewaarde- Norel J. Development of macular edema and impact on visual acuity in uveitis associated with juvenile idiopathic arthritis. Ocul Immunol Inflamm. 2015;23:67\u201373.","journal-title":"Ocul Immunol Inflamm"},{"key":"1310_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12969-015-0018-8","volume":"13","author":"ST Angeles-Han","year":"2015","unstructured":"Angeles-Han ST, McCracken C, Yeh S, Jenkins K, Stryker D, Rouster-Stevens K, et al. Characteristics of a cohort of children with juvenile idiopathic arthritis and JIA-associated uveitis. Pediatr Rheumatol Online J. 2015;13:19.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1310_CR23","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s10384-022-00927-y","volume":"66","author":"K Suzuki","year":"2022","unstructured":"Suzuki K, Ishihara M, Namba K, Ohno S, Goto H, Takase H, et al. Clinical features of ocular sarcoidosis: severe, refractory, and prolonged inflammation. Jpn J Ophthalmol. 2022;66:447\u201354.","journal-title":"Jpn J Ophthalmol"},{"key":"1310_CR24","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.1007\/s00417-022-05701-x","volume":"260","author":"K Nagahori","year":"2022","unstructured":"Nagahori K, Keino H, Nakayama M, Watanabe T, Ando Y, Hayashi I, et al. Clinical features and visual outcomes of ocular sarcoidosis at a tertiary referral center in Tokyo. Graefes Arch Clin Exp Ophthalmol. 2022;260:3357\u201363.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1310_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3109\/09273948.2015.1094095","volume":"25","author":"M Accorinti","year":"2017","unstructured":"Accorinti M, Pesci FR, Pirraglia MP, Abicca I, Pivetti-Pezzi P. Ocular Behcet\u2019s disease: changing patterns over time, complications and long-term visual prognosis. Ocul Immunol Inflamm. 2017;25:29\u201336.","journal-title":"Ocul Immunol Inflamm"},{"key":"1310_CR26","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","volume":"138","author":"I Tugal-Tutkun","year":"2004","unstructured":"Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138:373\u201380.","journal-title":"Am J Ophthalmol"},{"key":"1310_CR27","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2147\/DDDT.S166092","volume":"13","author":"S Koronis","year":"2019","unstructured":"Koronis S, Stavrakas P, Balidis M, Kozeis N, Tranos PG. Update in treatment of uveitic macular edema. Drug Des Devel Ther. 2019;13:667\u201380.","journal-title":"Drug Des Devel Ther"},{"key":"1310_CR28","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41433-023-02802-7","volume":"38","author":"MV Cicinelli","year":"2024","unstructured":"Cicinelli MV, Gerosolima C, Scandale P, Touhami S, Pohlmann D, Giocanti A, et al. Clinical and imaging biomarkers of response to intravitreal dexamethasone implant in eyes with non-infectious uveitic macular oedema. Eye (Lond). 2024;38:910\u20136.","journal-title":"Eye (Lond)"},{"key":"1310_CR29","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1097\/IAE.0b013e318285cc52","volume":"33","author":"MR Munk","year":"2013","unstructured":"Munk MR, Bolz M, Huf W, Sulzbacher F, Roberts P, Simader C, et al. Morphologic and functional evaluations during development, resolution, and relapse of uveitis-associated cystoid macular edema. Retina. 2013;33:1673\u201383.","journal-title":"Retina"},{"key":"1310_CR30","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2147\/OPTH.S180580","volume":"13","author":"H Massa","year":"2019","unstructured":"Massa H, Pipis SY, Adewoyin T, Vergados A, Patra S, Panos GD. Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges. Clin Ophthalmol. 2019;13:1761\u201377.","journal-title":"Clin Ophthalmol"},{"key":"1310_CR31","first-page":"2003","volume":"17","author":"NV Valentincic","year":"2011","unstructured":"Valentincic NV, de Groot-Mijnes JD, Kraut A, Korosec P, Hawlina M, Rothova A. Intraocular and serum cytokine profiles in patients with intermediate uveitis. Mol Vis. 2011;17:2003\u201310.","journal-title":"Mol Vis"},{"key":"1310_CR32","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ajo.2006.02.052","volume":"142","author":"B van Kooij","year":"2006","unstructured":"van Kooij B, Rothova A, Rijkers GT, de Groot-Mijnes JD. Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema. Am J Ophthalmol. 2006;142:192\u20134.","journal-title":"Am J Ophthalmol"},{"key":"1310_CR33","first-page":"2675","volume":"260","author":"A Takeda","year":"2022","unstructured":"Takeda A, Hasegawa E, Yawata N, Notomi S, Ishikawa K, Murakami Y, et al. Increased vitreous levels of B cell activation factor (BAFF) and soluble interleukin-6 receptor in patients with macular edema due to uveitis related to Behcet\u2019s disease and sarcoidosis. Graefes Arch Clin Exp Ophthalmol. 2022;260:2675\u201386.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1310_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1167\/tvst.8.5.32","volume":"8","author":"M Mesquida","year":"2019","unstructured":"Mesquida M, Drawnel F, Lait PJ, Copland DA, Stimpson ML, Llorenc V, et al. Modelling macular edema: the effect of il-6 and il-6r blockade on human blood-retinal barrier integrity in vitro. Translational Vision Sci Technol. 2019;8:32.","journal-title":"Translational Vision Sci Technol"},{"key":"1310_CR35","doi-asserted-by":"publisher","first-page":"6762","DOI":"10.1074\/jbc.RA117.001163","volume":"293","author":"P Baran","year":"2018","unstructured":"Baran P, Hansen S, Waetzig GH, Akbarzadeh M, Lamertz L, Huber HJ, et al. The balance of interleukin (IL)-6, IL-6.soluble IL-6 receptor (sIL-6R), and IL-6.sIL-6R.sgp130 complexes allows simultaneous classic and trans-signaling. J Biol Chem. 2018;293:6762\u201375.","journal-title":"J Biol Chem"},{"key":"1310_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.pathophys.2017.05.005","volume":"24","author":"F Zahir-Jouzdani","year":"2017","unstructured":"Zahir-Jouzdani F, Atyabi F, Mojtabavi N. Interleukin-6 participation in pathology of ocular diseases. Pathophysiology. 2017;24:123\u201331.","journal-title":"Pathophysiology"},{"key":"1310_CR37","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.ophtha.2020.08.035","volume":"128","author":"O Tomkins-Netzer","year":"2021","unstructured":"Tomkins-Netzer O, Lightman SL, Burke AE, Sugar EA, Lim LL, Jaffe GJ, et al. Seven-year outcomes of uveitic macular edema: the multicenter uveitis steroid treatment trial and follow-up study results. Ophthalmology. 2021;128:719\u201328.","journal-title":"Ophthalmology"},{"key":"1310_CR38","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ophtha.2018.08.021","volume":"126","author":"JE Thorne","year":"2019","unstructured":"Thorne JE, Sugar EA, Holbrook JT, Burke AE, Altaweel MM, Vitale AT, et al. PeriOcular triamcinolone vs. INTravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of Uveitic Macular Edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology. 2019;126:283\u201395.","journal-title":"Ophthalmology."},{"key":"1310_CR39","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1038\/s41433-021-01829-y","volume":"36","author":"M Alafaleq","year":"2022","unstructured":"Alafaleq M, Freund R, Penet MA, Fardeau C, Isnard-Bagnis C, du Tezenas Montcel S, et al. Ciclosporin A in bilateral auto-immune chronic posterior uveitis associated with macular oedema: a long-term observational safety and efficacy study. Eye Lond. 2022;36:2144\u201350.","journal-title":"Eye Lond"},{"key":"1310_CR40","doi-asserted-by":"crossref","unstructured":"Kunimi K, Usui Y, Asakage M, Maehara C, Tsubota K, Mitsuhashi R, et al. Anti-TNF-alpha therapy for refractory uveitis associated with behcet\u2019s syndrome and sarcoidosis: a single center study of 131 patients. Ocul Immunol Inflamm. 2020:1\u20138.","DOI":"10.1080\/09273948.2020.1791346"},{"key":"1310_CR41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ajo.2018.12.019","volume":"200","author":"N Vegas-Revenga","year":"2019","unstructured":"Vegas-Revenga N, Calvo-Rio V, Mesquida M, Adan A, Hernandez MV, Beltran E, et al. Anti-IL6-receptor tocilizumab in refractory and noninfectious uveitic cystoid macular edema: multicenter study of 25 patients. Am J Ophthalmol. 2019;200:85\u201394.","journal-title":"Am J Ophthalmol"},{"key":"1310_CR42","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.ophtha.2021.11.013","volume":"129","author":"M Leclercq","year":"2022","unstructured":"Leclercq M, Andrillon A, Maalouf G, Seve P, Bielefeld P, Gueudry J, et al. Anti-tumor necrosis factor alpha versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter study from the French uveitis network. Ophthalmology. 2022;129:520\u20139.","journal-title":"Ophthalmology"},{"key":"1310_CR43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3109\/09273948.2010.509530","volume":"19","author":"A van Ossewaarde- Norel","year":"2011","unstructured":"van Ossewaarde- Norel A, Rothova A. Clinical review: update on treatment of inflammatory macular edema. Ocul Immunol Inflamm. 2011;19:75\u201383.","journal-title":"Ocul Immunol Inflamm"},{"key":"1310_CR44","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1038\/eye.2008.388","volume":"23","author":"K Weiss","year":"2009","unstructured":"Weiss K, Steinbrugger I, Weger M, Ardjomand N, Maier R, Wegscheider BJ, et al. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye Lond. 2009;23:1812\u20138.","journal-title":"Eye Lond"},{"key":"1310_CR45","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2023.04.011","volume":"130","author":"NR Acharya","year":"2023","unstructured":"Multicenter Uveitis Steroid Treatment Trial Research Group WC, Acharya NR, Vitale AT, Sugar EA, Holbrook JT, Burke AE, et al. Intravitreal therapy for uveitic macular edema-ranibizumab versus methotrexate versus the dexamethasone implant: the MERIT trial results. Ophthalmology. 2023;130:914\u201323.","journal-title":"Ophthalmology"},{"key":"1310_CR46","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.ophtha.2024.11.021","volume":"132","author":"J Gonzales","year":"2025","unstructured":"Multicenter Uveitis Steroid Treatment Trial Research G, Gonzales J, Acharya NR, Sugar EA, Burke AE, Vitale AT, et al. Macular edema ranibizumab versus intravitreal anti-inflammatory therapy trial: 24-week outcomes of uveitic macular edema re-treatment. Ophthalmology. 2025;132:527\u201337.","journal-title":"Ophthalmology"},{"key":"1310_CR47","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.ajo.2014.01.020","volume":"157","author":"B Lehpamer","year":"2014","unstructured":"Lehpamer B, Moshier E, Pahk P, Goldberg N, Ackert J, Godbold J, et al. Epiretinal membranes in uveitic macular edema: effect on vision and response to therapy. Am J Ophthalmol. 2014;157:1048\u201355.","journal-title":"Am J Ophthalmol"},{"key":"1310_CR48","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1136\/bjo.2006.092965","volume":"90","author":"P Tranos","year":"2006","unstructured":"Tranos P, Scott R, Zambarakji H, Ayliffe W, Pavesio C, Charteris DG. The effect of pars plana vitrectomy on cystoid macular oedema associated with chronic uveitis: a randomised, controlled pilot study. Br J Ophthalmol. 2006;90:1107\u201310.","journal-title":"Br J Ophthalmol"},{"key":"1310_CR49","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ajo.2018.03.031","volume":"190","author":"CR Henry","year":"2018","unstructured":"Henry CR, Becker MD, Yang Y, Davis JL. Pars plana vitrectomy for the treatment of uveitis. Am J Ophthalmol. 2018;190:142\u20139.","journal-title":"Am J Ophthalmol"},{"key":"1310_CR50","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/eye.2016.133","volume":"30","author":"RS Grajewski","year":"2016","unstructured":"Grajewski RS, Boelke AC, Adler W, Meyer S, Caramoy A, Kirchhof B, et al. Spectral-domain optical coherence tomography findings of the macula in 500 consecutive patients with uveitis. Eye (Lond). 2016;30:1415\u201323.","journal-title":"Eye (Lond)"},{"key":"1310_CR51","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/eye.2011.338","volume":"26","author":"TF Cochrane","year":"2012","unstructured":"Cochrane TF, Silvestri G, McDowell C, Foot B, McAvoy CE. Acute retinal necrosis in the United Kingdom: results of a prospective surveillance study. Eye (Lond). 2012;26:370\u20137 (quiz 8).","journal-title":"Eye (Lond)"},{"key":"1310_CR52","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s10384-020-00809-1","volume":"65","author":"KH Sonoda","year":"2021","unstructured":"Sonoda KH, Hasegawa E, Namba K, Okada AA, Ohguro N, Goto H, et al. Epidemiology of uveitis in Japan: a 2016 retrospective nationwide survey. Jpn J Ophthalmol. 2021;65:184\u201390.","journal-title":"Jpn J Ophthalmol"},{"key":"1310_CR53","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s10384-014-0362-0","volume":"59","author":"H Takase","year":"2015","unstructured":"Takase H, Okada AA, Goto H, Mizuki N, Namba K, Ohguro N, et al. Development and validation of new diagnostic criteria for acute retinal necrosis. Jpn J Ophthalmol. 2015;59:14\u201320.","journal-title":"Jpn J Ophthalmol"},{"key":"1310_CR54","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s10384-012-0211-y","volume":"57","author":"C Iwahashi-Shima","year":"2013","unstructured":"Iwahashi-Shima C, Azumi A, Ohguro N, Okada AA, Kaburaki T, Goto H, et al. Acute retinal necrosis: factors associated with anatomic and visual outcomes. Jpn J Ophthalmol. 2013;57:98\u2013103.","journal-title":"Jpn J Ophthalmol"},{"key":"1310_CR55","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/09273948.2020.1789179","volume":"30","author":"H Takase","year":"2022","unstructured":"Takase H, Goto H, Namba K, Mizuki N, Okada AA, Ohguro N, et al. Clinical characteristics, management, and factors associated with poor visual prognosis of acute retinal necrosis. Ocul Immunol Inflamm. 2022;30:48\u201353.","journal-title":"Ocul Immunol Inflamm"},{"key":"1310_CR56","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1136\/bjo.75.8.450","volume":"75","author":"T Matsuo","year":"1991","unstructured":"Matsuo T, Morimoto K, Matsuo N. Factors associated with poor visual outcome in acute retinal necrosis. Br J Ophthalmol. 1991;75:450\u20134.","journal-title":"Br J Ophthalmol"},{"key":"1310_CR57","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.ophtha.2009.08.003","volume":"117","author":"R Wong","year":"2010","unstructured":"Wong R, Pavesio CE, Laidlaw DA, Williamson TH, Graham EM, Stanford MR. Acute retinal necrosis: the effects of intravitreal foscarnet and virus type on outcome. Ophthalmology. 2010;117:556\u201360.","journal-title":"Ophthalmology"},{"key":"1310_CR58","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3109\/09273948.2015.1115081","volume":"25","author":"CM Calvo","year":"2017","unstructured":"Calvo CM, Khan MA, Mehta S, Garg SJ, Dunn JP. Correlation of clinical outcomes with quantitative polymerase chain reaction DNA copy number in patients with acute retinal necrosis. Ocul Immunol Inflamm. 2017;25:246\u201352.","journal-title":"Ocul Immunol Inflamm"},{"key":"1310_CR59","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.survophthal.2023.09.004","volume":"69","author":"I Putera","year":"2024","unstructured":"Putera I, Ridwan AS, Dewi M, Cifuentes-Gonzalez C, Rojas-Carabali W, Sitompul R, et al. Antiviral treatment for acute retinal necrosis: a systematic review and meta-analysis. Surv Ophthalmol. 2024;69:67\u201384.","journal-title":"Surv Ophthalmol"},{"key":"1310_CR60","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/1120672118787438","volume":"29","author":"DY Kim","year":"2019","unstructured":"Kim DY, Jo J, Joe SG, Lee JY, Yoon YH, Kim JG. Clinical feature and visual prognosis of acute retinal necrosis according to the initially involved zone and extent: 10-year experience. Eur J Ophthalmol. 2019;29:244\u201350.","journal-title":"Eur J Ophthalmol"},{"key":"1310_CR61","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1007\/s00417-020-04701-z","volume":"258","author":"M Paolo","year":"2020","unstructured":"Paolo M, Marta Z, Stefania F, Viola T, Giacomo C, Arturo C, et al. Visual outcome and poor prognostic factors in acute retinal necrosis syndrome. Graefes Arch Clin Exp Ophthalmol. 2020;258:1851\u20136.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1310_CR62","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1001\/archopht.1989.01070020841024","volume":"107","author":"GN Holland","year":"1989","unstructured":"Holland GN, Buhles WC Jr., Mastre B, Kaplan HJ. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. Arch Ophthalmol. 1989;107:1759\u201366 (UCLA CMV Retinopathy. Study Group).","journal-title":"Arch Ophthalmol"},{"key":"1310_CR63","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41433-019-0587-8","volume":"34","author":"B Lei","year":"2020","unstructured":"Lei B, Zhou M, Wang Z, Chang Q, Xu G, Jiang R. Ultra-wide-field fundus imaging of acute retinal necrosis: clinical characteristics and visual significance. Eye (Lond). 2020;34:864\u201372.","journal-title":"Eye (Lond)"},{"key":"1310_CR64","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1038\/s41433-020-01332-w","volume":"35","author":"S Li","year":"2021","unstructured":"Li S, Sun L, Liu C, Wang W, Huang S, Zhang T, et al. Clinical features of ocular toxocariasis: a comparison between ultra-wide-field and conventional camera imaging. Eye (Lond). 2021;35:2855\u201363.","journal-title":"Eye (Lond)"},{"key":"1310_CR65","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s10384-022-00910-7","volume":"66","author":"Y Fukuda","year":"2022","unstructured":"Fukuda Y, Nakao S, Kohno RI, Ishikawa K, Shimokawa S, Shiose S, et al. Postoperative follow-up of submacular hemorrhage displacement treated with vitrectomy and subretinal injection of tissue plasminogen activator: ultrawide-field fundus autofluorescence imaging in gas-filled eyes. Jpn J Ophthalmol. 2022;66:264\u201370.","journal-title":"Jpn J Ophthalmol"},{"key":"1310_CR66","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/eye.2013.45","volume":"27","author":"CK Patel","year":"2013","unstructured":"Patel CK, Fung TH, Muqit MM, Mordant DJ, Brett J, Smith L, et al. Non-contact ultra-widefield imaging of retinopathy of prematurity using the Optos dual wavelength scanning laser ophthalmoscope. Eye (Lond). 2013;27:589\u201396.","journal-title":"Eye (Lond)"},{"key":"1310_CR67","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1038\/s41433-024-03207-w","volume":"38","author":"C Fukui","year":"2024","unstructured":"Fukui C, Takeda A, Hasegawa E, Asahara K, Shirane M, Tsutsui H, et al. Factors at the initial visit associated with poor visual outcomes in patients with acute retinal necrosis. Eye (Lond). 2024;38:2992\u20138.","journal-title":"Eye (Lond)"},{"key":"1310_CR68","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12348-015-0042-3","volume":"5","author":"TS Ward","year":"2015","unstructured":"Ward TS, Reddy AK. Fundus autofluorescence in the diagnosis and monitoring of acute retinal necrosis. J Ophthalmic Inflamm Infect. 2015;5:19.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"1310_CR69","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S0161-6420(86)33740-0","volume":"93","author":"MS Blumenkranz","year":"1986","unstructured":"Blumenkranz MS, Culbertson WW, Clarkson JG, Dix R. Treatment of the acute retinal necrosis syndrome with intravenous acyclovir. Ophthalmology. 1986;93:296\u2013300.","journal-title":"Ophthalmology"},{"key":"1310_CR70","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S0002-9394(14)76725-X","volume":"112","author":"DA Palay","year":"1991","unstructured":"Palay DA, Sternberg P Jr., Davis J, Lewis H, Holland GN, Mieler WF, et al. Decrease in the risk of bilateral acute retinal necrosis by acyclovir therapy. Am J Ophthalmol. 1991;112:250\u20135.","journal-title":"Am J Ophthalmol"},{"key":"1310_CR71","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1136\/bjophthalmol-2012-301983","volume":"97","author":"RW Wong","year":"2013","unstructured":"Wong RW, Jumper JM, McDonald HR, Johnson RN, Fu A, Lujan BJ, et al. Emerging concepts in the management of acute retinal necrosis. Br J Ophthalmol. 2013;97:545\u201352.","journal-title":"Br J Ophthalmol"},{"key":"1310_CR72","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/08820530802111192","volume":"23","author":"T Kawaguchi","year":"2008","unstructured":"Kawaguchi T, Spencer DB, Mochizuki M. Therapy for acute retinal necrosis. Semin Ophthalmol. 2008;23:285\u201390.","journal-title":"Semin Ophthalmol"},{"key":"1310_CR73","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ajo.2018.02.001","volume":"188","author":"J Baltinas","year":"2018","unstructured":"Baltinas J, Lightman S, Tomkins-Netzer O. Comparing treatment of acute retinal necrosis with either oral valacyclovir or intravenous acyclovir. Am J Ophthalmol. 2018;188:173\u201380.","journal-title":"Am J Ophthalmol"},{"key":"1310_CR74","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.ophtha.2016.11.007","volume":"124","author":"SD Schoenberger","year":"2017","unstructured":"Schoenberger SD, Kim SJ, Thorne JE, Mruthyunjaya P, Yeh S, Bakri SJ, et al. Diagnosis and treatment of acute retinal necrosis: a report by the American academy of ophthalmology. Ophthalmology. 2017;124:382\u201392.","journal-title":"Ophthalmology"},{"key":"1310_CR75","first-page":"133","volume":"111","author":"CJ Flaxel","year":"2013","unstructured":"Flaxel CJ, Yeh S, Lauer AK. Combination systemic and intravitreal antiviral therapy in the management of acute retinal necrosis syndrome (an American ophthalmological society thesis). Trans Am Ophthalmol Soc. 2013;111:133\u201344.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"1310_CR76","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.4103\/IJO.IJO_689_24","volume":"72","author":"A Kawali","year":"2024","unstructured":"Kawali A, Khanum A, Mishra SB, Sanjay S, Mahendradas P. Primary treatment failure in acute retinal necrosis - a comprehensive review. Indian J Ophthalmol. 2024;72:1694\u2013703.","journal-title":"Indian J Ophthalmol"},{"key":"1310_CR77","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10384-024-01148-1","volume":"69","author":"SH Jung","year":"2025","unstructured":"Jung SH, Yi SU, Park YH. Retinal detachment after acute retinal necrosis: a retrospective analysis of hospitalized patients. Jpn J Ophthalmol. 2025;69:131\u20138.","journal-title":"Jpn J Ophthalmol"},{"key":"1310_CR78","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1097\/IAE.0000000000002971","volume":"41","author":"XY Zhao","year":"2021","unstructured":"Zhao XY, Meng LH, Zhang WF, Wang DY, Chen YX. Retinal detachment after acute retinal necrosis and the efficacies of different interventions: a systematic review and metaanalysis. Retina. 2021;41:965\u201378.","journal-title":"Retina"},{"key":"1310_CR79","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0161-6420(84)34107-0","volume":"91","author":"JG Clarkson","year":"1984","unstructured":"Clarkson JG, Blumenkranz MS, Culbertson WW, Flynn HW Jr, Lewis ML. Retinal detachment following the acute retinal necrosis syndrome. Ophthalmology. 1984;91:1665\u20138.","journal-title":"Ophthalmology"},{"key":"1310_CR80","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1016\/j.ophtha.2009.03.029","volume":"116","author":"J Hillenkamp","year":"2009","unstructured":"Hillenkamp J, Nolle B, Bruns C, Rautenberg P, Fickenscher H, Roider J. Acute retinal necrosis: clinical features, early vitrectomy, and outcomes. Ophthalmology. 2009;116:1971-5 e2.","journal-title":"Ophthalmology"},{"key":"1310_CR81","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s10384-009-0698-z","volume":"53","author":"T Ishida","year":"2009","unstructured":"Ishida T, Sugamoto Y, Sugita S, Mochizuki M. Prophylactic vitrectomy for acute retinal necrosis. Jpn J Ophthalmol. 2009;53:486\u20139.","journal-title":"Jpn J Ophthalmol"},{"key":"1310_CR82","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1080\/09273948.2020.1800051","volume":"30","author":"S Fan","year":"2022","unstructured":"Fan S, Lin D, Wang Y. Role of prophylactic vitrectomy in acute retinal necrosis in preventing rhegmatogenous retinal detachment: systematic review and meta-analysis. Ocul Immunol Inflamm. 2022;30:515\u20139.","journal-title":"Ocul Immunol Inflamm"},{"key":"1310_CR83","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.ophtha.2024.07.020","volume":"131","author":"I Lains","year":"2024","unstructured":"Lains I, Ivanov A, Ross C, Hall N, Elze T, Lorch A, et al. Treatment regimen and outcomes in acute retinal necrosis: an IRIS(R) registry study. Ophthalmology. 2024;131:1468\u201370.","journal-title":"Ophthalmology"},{"key":"1310_CR84","doi-asserted-by":"publisher","first-page":"e0323822","DOI":"10.1371\/journal.pone.0323822","volume":"20","author":"Y Usui","year":"2025","unstructured":"Usui Y, Kinouchi R, Nakano S, Iwahashi C, Hase K, Nagata K, et al. Protocol for Japan-acute retinal necrosis (J-ARN) registry: a combined prospective and retrospective cohort study. PLoS ONE. 2025;20:e0323822.","journal-title":"PLoS ONE"},{"key":"1310_CR85","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/ceo.14443","volume":"53","author":"M Ostrovsky","year":"2025","unstructured":"Ostrovsky M, Sela TC, Habot-Wilner Z. Comparison of various treatment modalities in patients with primary vitreoretinal lymphoma: a systematic review and meta-analysis. Clin Exp Ophthalmol. 2025;53:84\u201399.","journal-title":"Clin Exp Ophthalmol"},{"key":"1310_CR86","first-page":"93","volume":"15","author":"CC Chan","year":"2013","unstructured":"Chan CC, Sen HN. Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma. Discov Med. 2013;15:93\u2013100.","journal-title":"Discov Med"},{"key":"1310_CR87","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10384-023-00997-6","volume":"67","author":"T Kaburaki","year":"2023","unstructured":"Kaburaki T, Taoka K. Diagnosis and management of vitreoretinal lymphoma: present and future treatment perspectives. Jpn J Ophthalmol. 2023;67:363\u201381.","journal-title":"Jpn J Ophthalmol"},{"key":"1310_CR88","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jamaophthalmol.2013.569","volume":"131","author":"SD Levasseur","year":"2013","unstructured":"Levasseur SD, Wittenberg LA, White VA. Vitreoretinal lymphoma: a 20-year review of incidence, clinical and cytologic features, treatment, and outcomes. JAMA Ophthalmol. 2013;131:50\u20135.","journal-title":"JAMA Ophthalmol"},{"key":"1310_CR89","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10384-006-0383-4","volume":"51","author":"H Goto","year":"2007","unstructured":"Goto H, Mochizuki M, Yamaki K, Kotake S, Usui M, Ohno S. Epidemiological survey of intraocular inflammation in Japan. Jpn J Ophthalmol. 2007;51:41\u20134.","journal-title":"Jpn J Ophthalmol"},{"key":"1310_CR90","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s10384-012-0158-z","volume":"56","author":"N Ohguro","year":"2012","unstructured":"Ohguro N, Sonoda KH, Takeuchi M, Matsumura M, Mochizuki M. The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol. 2012;56:432\u20135.","journal-title":"Jpn J Ophthalmol"},{"key":"1310_CR91","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1136\/bjophthalmol-2018-313491","volume":"103","author":"A Marchese","year":"2019","unstructured":"Marchese A, Miserocchi E, Giuffre C, Cicinelli MV, Querques G, Bandello F, et al. Aurora borealis and string of pearls in vitreoretinal lymphoma: patterns of vitreous haze. Br J Ophthalmol. 2019;103:1656\u20139.","journal-title":"Br J Ophthalmol"},{"key":"1310_CR92","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.oret.2023.08.012","volume":"8","author":"International Vitreoretinal BCLRIG","year":"2024","unstructured":"International Vitreoretinal BCLRIG. Presentation, diagnostic testing and initial treatment of vitreoretinal lymphoma. Ophthalmol Retina. 2024;8:72\u201380.","journal-title":"Ophthalmol Retina"},{"key":"1310_CR93","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1080\/09273948.2021.1878233","volume":"29","author":"D Carbonell","year":"2021","unstructured":"Carbonell D, Mahajan S, Chee SP, Sobolewska B, Agrawal R, Bulow T, et al. Consensus recommendations for the diagnosis of vitreoretinal lymphoma. Ocul Immunol Inflamm. 2021;29:507\u201320.","journal-title":"Ocul Immunol Inflamm"},{"key":"1310_CR94","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/IAE.0b013e3181b408a2","volume":"30","author":"T Ishida","year":"2010","unstructured":"Ishida T, Ohno-Matsui K, Kaneko Y, Tobita H, Shimada N, Takase H, et al. Fundus autofluorescence patterns in eyes with primary intraocular lymphoma. Retina. 2010;30:23\u201332.","journal-title":"Retina"},{"key":"1310_CR95","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/IAE.0b013e31829977fa","volume":"34","author":"M Casady","year":"2014","unstructured":"Casady M, Faia L, Nazemzadeh M, Nussenblatt R, Chan CC, Sen HN. Fundus autofluorescence patterns in primary intraocular lymphoma. Retina. 2014;34:366\u201372.","journal-title":"Retina"},{"key":"1310_CR96","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1136\/bjophthalmol-2017-311612","volume":"102","author":"RJ Barry","year":"2018","unstructured":"Barry RJ, Tasiopoulou A, Murray PI, Patel PJ, Sagoo MS, Denniston AK, et al. Characteristic optical coherence tomography findings in patients with primary vitreoretinal lymphoma: a novel aid to early diagnosis. Br J Ophthalmol. 2018;102:1362\u20136.","journal-title":"Br J Ophthalmol"},{"key":"1310_CR97","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/ceo.14197","volume":"51","author":"W Guan","year":"2023","unstructured":"Guan W, Xiao Y, Zhao H, Hu F, Chen C, Peng X. Spectral-domain optical coherence tomography biomarkers in vitreoretinal lymphoma. Clin Exp Ophthalmol. 2023;51:144\u201353.","journal-title":"Clin Exp Ophthalmol"},{"key":"1310_CR98","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/APO.0000000000000274","volume":"9","author":"LA Dalvin","year":"2020","unstructured":"Dalvin LA, Lim LS, Ancona-Lezama D, Mazloumi M, Chang M, Porcu P, et al. Clinical features predictive of survival in patients with vitreoretinal lymphoma: analysis of 70 patients at a single ocular oncology center. Asia Pac J Ophthalmol (Phila). 2020;9:110\u20136.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"1310_CR99","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10384-009-0662-y","volume":"53","author":"S Sugita","year":"2009","unstructured":"Sugita S, Takase H, Sugamoto Y, Arai A, Miura O, Mochizuki M. Diagnosis of intraocular lymphoma by polymerase chain reaction analysis and cytokine profiling of the vitreous fluid. Jpn J Ophthalmol. 2009;53:209\u201314.","journal-title":"Jpn J Ophthalmol"},{"key":"1310_CR100","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/sj.eye.6702965","volume":"22","author":"L Intzedy","year":"2008","unstructured":"Intzedy L, Teoh SC, Hogan A, Mangwana S, Mayer EJ, Dick AD, et al. Cytopathological analysis of vitreous in intraocular lymphoma. Eye (Lond). 2008;22:289\u201393.","journal-title":"Eye (Lond)"},{"key":"1310_CR101","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13000-016-0479-1","volume":"11","author":"S Kase","year":"2016","unstructured":"Kase S, Namba K, Iwata D, Mizuuchi K, Kitaichi N, Tagawa Y, et al. Diagnostic efficacy of cell block method for vitreoretinal lymphoma. Diagn Pathol. 2016;11:29.","journal-title":"Diagn Pathol"},{"key":"1310_CR102","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s00417-019-04266-6","volume":"257","author":"T Ito","year":"2019","unstructured":"Ito T, Takeda A, Fujiwara K, Hasegawa E, Nakao S, Ohishi Y, et al. Risk factors for failure of vitrectomy cell block technique in cytological diagnosis of vitreoretinal lymphoma. Graefes Arch Clin Exp Ophthalmol. 2019;257:1029\u201336.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1310_CR103","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s00417-003-0749-y","volume":"241","author":"SE Coupland","year":"2003","unstructured":"Coupland SE, Bechrakis NE, Anastassiou G, Foerster AM, Heiligenhaus A, Pleyer U, et al. Evaluation of vitrectomy specimens and chorioretinal biopsies in the diagnosis of primary intraocular lymphoma in patients with Masquerade syndrome. Graefes Arch Clin Exp Ophthalmol. 2003;241:860\u201370.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1310_CR104","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2021.1873394","author":"R Tanaka","year":"2021","unstructured":"Tanaka R, Kaburaki T, Taoka K, Karakawa A, Tsuji H, Nishikawa M, et al. More accurate diagnosis of vitreoretinal lymphoma using a combination of diagnostic test results: a prospective observational study. Ocul Immunol Inflamm. 2021. https:\/\/doi.org\/10.1080\/09273948.2021.1873394.","journal-title":"Ocul Immunol Inflamm"},{"key":"1310_CR105","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3324\/haematol.2021.278613","volume":"109","author":"M Roschewski","year":"2024","unstructured":"Roschewski M, Hodson DJ. Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy. Haematologica. 2024;109:388\u2013400.","journal-title":"Haematologica"},{"key":"1310_CR106","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1080\/09273948.2019.1657903","volume":"29","author":"H Shi","year":"2021","unstructured":"Shi H, Zhou X, Chen B, Xiao J, Li Y, Zhou X, et al. Clinical relevance of the high prevalence of myd88 l265p mutated vitreoretinal lymphoma identified by droplet digital polymerase chain reaction. Ocul Immunol Inflamm. 2021;29:448\u201355.","journal-title":"Ocul Immunol Inflamm"},{"key":"1310_CR107","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1080\/09273948.2020.1787460","volume":"29","author":"C Giuffre","year":"2021","unstructured":"Giuffre C, Cicinelli MV, Marchese A, Modorati GM, Brambati M, Ferreri AJM, et al. Clinical experience in a large cohort of patients with vitreoretinal lymphoma in a single center. Ocul Immunol Inflamm. 2021;29:472\u20138.","journal-title":"Ocul Immunol Inflamm"},{"key":"1310_CR108","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1182\/blood-2015-01-620518","volume":"126","author":"I Bonzheim","year":"2015","unstructured":"Bonzheim I, Giese S, Deuter C, Susskind D, Zierhut M, Waizel M, et al. High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates. Blood. 2015;126:76\u20139.","journal-title":"Blood"},{"key":"1310_CR109","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1097\/IAE.0000000000000996","volume":"36","author":"H Raja","year":"2016","unstructured":"Raja H, Salomao DR, Viswanatha DS, Pulido JS. Prevalence of Myd88 L265p mutation in histologically proven, diffuse large B-Cell vitreoretinal lymphoma. Retina. 2016;36:624\u20138.","journal-title":"Retina"},{"key":"1310_CR110","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1001\/jamaophthalmol.2018.2887","volume":"136","author":"LS Hiemcke-Jiwa","year":"2018","unstructured":"Hiemcke-Jiwa LS, Ten Dam-van Loon NH, Leguit RJ, Nierkens S, Ossewaarde-van Norel J, de Boer JH, et al. Potential diagnosis of vitreoretinal lymphoma by detection of MYD88 mutation in aqueous humor with ultrasensitive droplet digital polymerase chain reaction. JAMA Ophthalmol. 2018;136:1098\u2013104.","journal-title":"JAMA Ophthalmol"},{"key":"1310_CR111","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/ejh.13191","volume":"102","author":"I Yonese","year":"2019","unstructured":"Yonese I, Takase H, Yoshimori M, Onozawa E, Tsuzura A, Miki T, et al. CD79B mutations in primary vitreoretinal lymphoma: diagnostic and prognostic potential. Eur J Haematol. 2019;102:191\u20136.","journal-title":"Eur J Haematol"},{"key":"1310_CR112","first-page":"1598","volume":"6","author":"I Bonzheim","year":"2022","unstructured":"Bonzheim I, Sander P, Salmeron-Villalobos J, Susskind D, Szurman P, Gekeler F, et al. The molecular hallmarks of primary and secondary vitreoretinal lymphoma. Blood Adv. 2022;6:1598\u2013607.","journal-title":"Blood Adv"},{"key":"1310_CR113","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.3324\/haematol.2021.279908","volume":"107","author":"X Wang","year":"2022","unstructured":"Wang X, Su W, Gao Y, Feng Y, Wang X, Chen X, et al. A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas. Haematologica. 2022;107:2154\u201362.","journal-title":"Haematologica"},{"key":"1310_CR114","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-Cell lymphoma. N Engl J Med. 2018;378:1396\u2013407.","journal-title":"N Engl J Med"},{"key":"1310_CR115","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1111\/cas.15427","volume":"113","author":"S Fukuhara","year":"2022","unstructured":"Fukuhara S, Oshikawa-Kumade Y, Kogure Y, Shingaki S, Kariyazono H, Kikukawa Y, et al. Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies. Cancer Sci. 2022;113:2763\u201377.","journal-title":"Cancer Sci"},{"key":"1310_CR116","first-page":"3641","volume":"109","author":"K Yoshifuji","year":"2024","unstructured":"Yoshifuji K, Sadato D, Toya T, Motomura Y, Hirama C, Takase H, et al. Impact of genetic alterations on central nervous system progression of primary vitreoretinal lymphoma. Haematologica. 2024;109:3641\u20139.","journal-title":"Haematologica"},{"key":"1310_CR117","doi-asserted-by":"publisher","first-page":"338","DOI":"10.3390\/cancers14020338","volume":"14","author":"D Marino","year":"2022","unstructured":"Marino D, Pizzi M, Kotova I, Schmidt R, Schroder C, Guzzardo V, et al. High ETV6 levels support aggressive B lymphoma cell survival and predict poor outcome in diffuse large B-Cell lymphoma patients. Cancers (Basel). 2022;14:338.","journal-title":"Cancers (Basel)"},{"key":"1310_CR118","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/leu.2016.243","volume":"31","author":"Y Xia","year":"2017","unstructured":"Xia Y, Xu-Monette ZY, Tzankov A, Li X, Manyam GC, Murty V, et al. Loss of PRDM1\/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia. 2017;31:625\u201336.","journal-title":"Leukemia"},{"key":"1310_CR119","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/cac2.12344","volume":"42","author":"X Chen","year":"2022","unstructured":"Chen X, Hu Y, Su W, Yang S, Wang X, Zhang P, et al. Diagnostic value of genetic mutation analysis and mutation profiling of cell-free DNA in intraocular fluid for vitreoretinal lymphoma. Cancer Commun. 2022;42:1217\u201321.","journal-title":"Cancer Commun"},{"key":"1310_CR120","doi-asserted-by":"publisher","first-page":"e52385","DOI":"10.1371\/journal.pone.0052385","volume":"8","author":"S Fisson","year":"2013","unstructured":"Fisson S, Ouakrim H, Touitou V, Baudet S, Ben Abdelwahed R, Donnou S, et al. Cytokine profile in human eyes: contribution of a new cytokine combination for differential diagnosis between intraocular lymphoma or uveitis. PLoS ONE. 2013;8:e52385.","journal-title":"PLoS ONE"},{"key":"1310_CR121","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.1167\/iovs.15-17465","volume":"56","author":"A Takeda","year":"2015","unstructured":"Takeda A, Yoshikawa H, Fukuhara T, Hikita S, Hijioka K, Otomo T, et al. Distinct profiles of soluble cytokine receptors between b-cell vitreoretinal lymphoma and uveitis. Invest Ophthalmol Vis Sci. 2015;56:7516\u201323.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1310_CR122","doi-asserted-by":"publisher","first-page":"15715","DOI":"10.1038\/s41598-020-72962-z","volume":"10","author":"A Takeda","year":"2020","unstructured":"Takeda A, Hasegawa E, Nakao S, Ishikawa K, Murakami Y, Hisatomi T, et al. Vitreous levels of interleukin-35 as a prognostic factor in B-cell vitreoretinal lymphoma. Sci Rep. 2020;10:15715.","journal-title":"Sci Rep"},{"key":"1310_CR123","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/aos.14036","volume":"97","author":"J de Hoog","year":"2019","unstructured":"de Hoog J, Dik WA, Lu L, Heezen KC, Ten Berge JC, Swagemakers SMA, et al. Combined cellular and soluble mediator analysis for improved diagnosis of vitreoretinal lymphoma. Acta Ophthalmol. 2019;97:626\u201332.","journal-title":"Acta Ophthalmol"},{"key":"1310_CR124","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1167\/iovs.66.3.38","volume":"66","author":"R Sugawara","year":"2025","unstructured":"Sugawara R, Usui Y, Saito A, Nezu N, Komatsu H, Tsubota K, et al. An approach to predict intraocular diseases by machine learning based on vitreous humor immune mediator profile. Invest Ophthalmol Vis Sci. 2025;66:38.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1310_CR125","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1167\/iovs.64.15.2","volume":"64","author":"H Komatsu","year":"2023","unstructured":"Komatsu H, Usui Y, Tsubota K, Fujii R, Yamaguchi T, Maruyama K, et al. Vitreous humor proteomic profile in patients with vitreoretinal lymphoma. Invest Ophthalmol Vis Sci. 2023;64:2.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1310_CR126","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ajo.2013.12.014","volume":"157","author":"J Tuo","year":"2014","unstructured":"Tuo J, Shen D, Yang HH, Chan CC. Distinct microRNA-155 expression in the vitreous of patients with primary vitreoretinal lymphoma and uveitis. Am J Ophthalmol. 2014;157:728\u201334.","journal-title":"Am J Ophthalmol"},{"key":"1310_CR127","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.3390\/jcm9061844","volume":"9","author":"T Minezaki","year":"2020","unstructured":"Minezaki T, Usui Y, Asakage M, Takanashi M, Shimizu H, Nezu N, et al. High-throughput MicroRNA profiling of vitreoretinal lymphoma: vitreous and serum MicroRNA profiles distinct from uveitis. J Clin Med. 2020;9:1844.","journal-title":"J Clin Med"},{"key":"1310_CR128","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1634\/theoncologist.2011-0210","volume":"16","author":"CC Chan","year":"2011","unstructured":"Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist. 2011;16:1589\u201399.","journal-title":"Oncologist"},{"key":"1310_CR129","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40942-018-0120-4","volume":"4","author":"JS Pulido","year":"2018","unstructured":"Pulido JS, Johnston PB, Nowakowski GS, Castellino A, Raja H. The diagnosis and treatment of primary vitreoretinal lymphoma: a review. Int J Retina Vitreous. 2018;4:18.","journal-title":"Int J Retina Vitreous"},{"key":"1310_CR130","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/bjh.15661","volume":"184","author":"CP Fox","year":"2019","unstructured":"Fox CP, Phillips EH, Smith J, Linton K, Gallop-Evans E, Hemmaway C, et al. Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. Br J Haematol. 2019;184:348\u201363.","journal-title":"Br J Haematol"},{"key":"1310_CR131","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1097\/CCO.0000000000000776","volume":"33","author":"D Malaise","year":"2021","unstructured":"Malaise D, Houillier C, Touitou V, Choquet S, Maloum K, Le Garff-Tavernier M, et al. Primary vitreoretinal lymphoma: short review of the literature, results of a European survey and French guidelines of the LOC network for diagnosis, treatment and follow-up. Curr Opin Oncol. 2021;33:420\u201331.","journal-title":"Curr Opin Oncol"},{"key":"1310_CR132","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/archopht.1997.01100160322009","volume":"115","author":"BC Fishburne","year":"1997","unstructured":"Fishburne BC, Wilson DJ, Rosenbaum JT, Neuwelt EA. Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol. 1997;115:1152\u20136.","journal-title":"Arch Ophthalmol"},{"key":"1310_CR133","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1136\/bjo.2007.127928","volume":"92","author":"S Frenkel","year":"2008","unstructured":"Frenkel S, Hendler K, Siegal T, Shalom E, Pe\u2019er J. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol. 2008;92:383\u20138.","journal-title":"Br J Ophthalmol"},{"key":"1310_CR134","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1212\/01.wnl.0000327672.04729.8c","volume":"71","author":"SA Grimm","year":"2008","unstructured":"Grimm SA, McCannel CA, Omuro AM, Ferreri AJ, Blay JY, Neuwelt EA, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL collaborative group report. Neurology. 2008;71:1355\u201360.","journal-title":"Neurology"},{"key":"1310_CR135","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/bjh.17451","volume":"194","author":"Z Habot-Wilner","year":"2021","unstructured":"Habot-Wilner Z, Frenkel S, Pe\u2019er J. Efficacy and safety of intravitreal methotrexate for vitreo-retinal lymphoma - 20 years of experience. Br J Haematol. 2021;194:92\u2013100.","journal-title":"Br J Haematol"},{"key":"1310_CR136","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/bjh.14848","volume":"179","author":"T Kaburaki","year":"2017","unstructured":"Kaburaki T, Taoka K, Matsuda J, Yamashita H, Matsuda I, Tsuji H, et al. Combined intravitreal methotrexate and immunochemotherapy followed by reduced-dose whole-brain radiotherapy for newly diagnosed B-cell primary intraocular lymphoma. Br J Haematol. 2017;179:246\u201355.","journal-title":"Br J Haematol"},{"key":"1310_CR137","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","volume":"22","author":"MR Smith","year":"2003","unstructured":"Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359\u201368.","journal-title":"Oncogene"},{"key":"1310_CR138","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1167\/tvst.1.3.1","volume":"1","author":"N Hashida","year":"2012","unstructured":"Hashida N, Ohguro N, Nishida K. Efficacy and complications of intravitreal rituximab injection for treating primary vitreoretinal lymphoma. Transl Vis Sci Technol. 2012;1:1.","journal-title":"Transl Vis Sci Technol"},{"key":"1310_CR139","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1136\/bjophthalmol-2013-304043","volume":"98","author":"KL Larkin","year":"2014","unstructured":"Larkin KL, Saboo US, Comer GM, Forooghian F, Mackensen F, Merrill P, et al. Use of intravitreal rituximab for treatment of vitreoretinal lymphoma. Br J Ophthalmol. 2014;98:99\u2013103.","journal-title":"Br J Ophthalmol"},{"key":"1310_CR140","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1080\/10428190600632881","volume":"47","author":"K Isobe","year":"2006","unstructured":"Isobe K, Ejima Y, Tokumaru S, Shikama N, Suzuki G, Takemoto M, et al. Treatment of primary intraocular lymphoma with radiation therapy: a multi-institutional survey in Japan. Leuk Lymphoma. 2006;47:1800\u20135.","journal-title":"Leuk Lymphoma"},{"key":"1310_CR141","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ajh.25414","volume":"94","author":"MI de la Fuente","year":"2019","unstructured":"de la Fuente MI, Alderuccio JP, Reis IM, Omuro A, Markoe A, Echegaray JJ, et al. Bilateral radiation therapy followed by methotrexate\u2010based chemotherapy for primary vitreoretinal lymphoma. Am J Hematol. 2019;94:455\u201360.","journal-title":"Am J Hematol"},{"key":"1310_CR142","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/ajh.26199","volume":"96","author":"M Lam","year":"2021","unstructured":"Lam M, Touitou V, Choquet S, Cassoux N, Ghesquieres H, Kodjikian L, et al. Intravenous high\u2010dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: an <scp>LOC<\/scp> network study. Am J Hematol. 2021;96:823\u201333.","journal-title":"Am J Hematol"},{"key":"1310_CR143","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ajh.25350","volume":"94","author":"A Castellino","year":"2019","unstructured":"Castellino A, Pulido JS, Johnston PB, Ristow KM, Nora Bennani N, Inwards DJ, et al. Role of systemic high\u2010dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: a single center experience 1990\u20102018. Am J Hematol. 2019;94:291\u20138.","journal-title":"Am J Hematol"},{"key":"1310_CR144","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41409-024-02477-y","volume":"60","author":"A Mainguy","year":"2025","unstructured":"Mainguy A, Soussain C, Touitou V, Bennedjai A, Kodjikian L, Ghesquieres H, et al. High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study. Bone Marrow Transplant. 2025;60:297\u2013304.","journal-title":"Bone Marrow Transplant"},{"key":"1310_CR145","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/cas.13012","volume":"107","author":"H Akiyama","year":"2016","unstructured":"Akiyama H, Takase H, Kubo F, Miki T, Yamamoto M, Tomita M, et al. High-dose methotrexate following intravitreal methotrexate administration in preventing central nervous system involvement of primary intraocular lymphoma. Cancer Sci. 2016;107:1458\u201364.","journal-title":"Cancer Sci"},{"key":"1310_CR146","doi-asserted-by":"publisher","first-page":"e71092","DOI":"10.1002\/cam4.71092","volume":"14","author":"J Gao","year":"2025","unstructured":"Gao J, Lv LW, Yang J, Wang HN, Wang L. Exploration of the optimal reatment modality for vitreoretinal lymphoma: a PRISMA compliant meta-analysis and systematic review. Cancer Med. 2025;14:e71092.","journal-title":"Cancer Med"},{"key":"1310_CR147","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1093\/annonc\/mdm340","volume":"18","author":"SA Grimm","year":"2007","unstructured":"Grimm SA, Pulido JS, Jahnke K, Schiff D, Hall AJ, Shenkier TN, et al. Primary intraocular lymphoma: an international primary central nervous system lymphoma collaborative group report. Ann Oncol. 2007;18:1851\u20135.","journal-title":"Ann Oncol"},{"key":"1310_CR148","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1001\/jamaophthalmol.2014.4755","volume":"133","author":"A Riemens","year":"2015","unstructured":"Riemens A, Bromberg J, Touitou V, Sobolewska B, Missotten T, Baarsma S, et al. Treatment strategies in primary vitreoretinal lymphoma: a 17-center European collaborative study. JAMA Ophthalmol. 2015;133:191\u20137.","journal-title":"JAMA Ophthalmol"},{"key":"1310_CR149","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.survophthal.2021.03.004","volume":"66","author":"V Raval","year":"2021","unstructured":"Raval V, Binkley E, Aronow ME, Valenzuela J, Peereboom DM, Singh AD. Primary central nervous system lymphoma \u2013 ocular variant: an interdisciplinary review on management. Surv Ophthalmol. 2021;66:1009\u201320.","journal-title":"Surv Ophthalmol"},{"key":"1310_CR150","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/cas.14347","volume":"111","author":"A Arai","year":"2020","unstructured":"Arai A, Takase H, Yoshimori M, Yamamoto K, Mochizuki M, Miura O. Gene expression profiling of primary vitreoretinal lymphoma. Cancer Sci. 2020;111:1417\u201321.","journal-title":"Cancer Sci"},{"key":"1310_CR151","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.tips.2024.06.006","volume":"45","author":"A Cool","year":"2024","unstructured":"Cool A, Nong T, Montoya S, Taylor J. BTK inhibitors: past, present, and future. Trends Pharmacol Sci. 2024;45:691\u2013707.","journal-title":"Trends Pharmacol Sci"},{"key":"1310_CR152","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13045-022-01353-w","volume":"15","author":"A Alu","year":"2022","unstructured":"Alu A, Lei H, Han X, Wei Y, Wei X. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies. J Hematol Oncol. 2022;15:138.","journal-title":"J Hematol Oncol"},{"key":"1310_CR153","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00280-018-3546-3","volume":"81","author":"L Goldwirt","year":"2018","unstructured":"Goldwirt L, Beccaria K, Ple A, Sauvageon H, Mourah S. Ibrutinib brain distribution: a preclinical study. Cancer Chemother Pharmacol. 2018;81:783\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1310_CR154","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","volume":"117","author":"C Soussain","year":"2019","unstructured":"Soussain C, Choquet S, Blonski M, Leclercq D, Houillier C, Rezai K, et al. Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II \u201cproof-of-concept\u201d iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer. 2019;117:121\u201330.","journal-title":"Eur J Cancer"},{"key":"1310_CR155","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa2114110","volume":"386","author":"E Wang","year":"2022","unstructured":"Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, et al. Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors. N Engl J Med. 2022;386:735\u201343.","journal-title":"N Engl J Med"},{"key":"1310_CR156","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/bjh.18418","volume":"200","author":"S Nakhoda","year":"2023","unstructured":"Nakhoda S, Vistarop A, Wang YL. Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 2023;200:137\u201349.","journal-title":"Br J Haematol"},{"key":"1310_CR157","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","volume":"23","author":"Y Narita","year":"2021","unstructured":"Narita Y, Nagane M, Mishima K, Terui Y, Arakawa Y, Yonezawa H, et al. Phase I\/II study of tirabrutinib, a second-generation Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma. Neuro Oncol. 2021;23:122\u201333.","journal-title":"Neuro Oncol"},{"key":"1310_CR158","unstructured":"Trials JRoC. Phase II, double-blind, comparative study of ONO-4059 (a Bruton\u2019s tyrosine kinase inhibitor) for primary intraocular lymphoma. https:\/\/jrct.mhlw.go.jp\/latest-detail\/jRCT2031200383 Accessed 18 July 2025 (in Japanese)."},{"key":"1310_CR159","first-page":"188616","volume":"1876","author":"MS Tomar","year":"2021","unstructured":"Tomar MS, Kumar A, Srivastava C, Shrivastava A. Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochimica et Biophysica Acta (BBA). 2021;1876:188616.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"1310_CR160","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1182\/blood.2019003073","volume":"135","author":"M Baron","year":"2020","unstructured":"Baron M, Belin L, Cassoux N, Fardeau C, Blaizeau M, Soussain C, et al. Temozolomide is effective and well tolerated in patients with primary vitreoretinal lymphoma. Blood. 2020;135:1811\u20135.","journal-title":"Blood"},{"key":"1310_CR161","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2023.2705","volume":"20","author":"CW Zhang","year":"2024","unstructured":"Zhang CW, Wang YN, Ge XL. Lenalidomide use in multiple myeloma (Review). Mol Clin Oncol. 2024;20:7.","journal-title":"Mol Clin Oncol"},{"key":"1310_CR162","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/annonc\/mdz032","volume":"30","author":"H Ghesquieres","year":"2019","unstructured":"Ghesquieres H, Chevrier M, Laadhari M, Chinot O, Choquet S, Molucon-Chabrot C, et al. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed\/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective \u2018proof of concept\u2019 phase II study of the French oculo-cerebral lymphoma (LOC) network and the lymphoma study association (LYSA) dagger. Ann Oncol. 2019;30:621\u20138.","journal-title":"Ann Oncol"},{"key":"1310_CR163","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/ajh.27316","volume":"99","author":"S Choquet","year":"2024","unstructured":"Choquet S, Soussain C, Azar N, Morel V, Metz C, Ursu R, et al. CAR T-cell therapy induces a high rate of prolonged remission in relapsed primary CNS lymphoma: real-life results of the LOC network. Am J Hematol. 2024;99:1240\u20139.","journal-title":"Am J Hematol"},{"key":"1310_CR164","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/bloodadvances.2022008525","volume":"7","author":"MR Cook","year":"2023","unstructured":"Cook MR, Dorris CS, Makambi KH, Luo Y, Munshi PN, Donato M, et al. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2023;7:32\u20139.","journal-title":"Blood Adv"},{"key":"1310_CR165","doi-asserted-by":"publisher","first-page":"e213501","DOI":"10.1212\/WNL.0000000000213501","volume":"104","author":"H Hernandez-Tost","year":"2025","unstructured":"Hernandez-Tost H, Weiss N, Choquet S, Birzu C, Le Guennec L, Mersali S, et al. Neurotoxicity in patients with CNS lymphomas treated with CAR T-cell therapy: a study from the French oculo-cerebral lymphoma network. Neurology. 2025;104:e213501.","journal-title":"Neurology"},{"key":"1310_CR166","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1038\/s41433-024-03324-6","volume":"38","author":"M Masalkhi","year":"2024","unstructured":"Masalkhi M, Wahhoud N, Elhassadi E. Next-gen oncology: the role of CAR-T cells against ocular lymphoma and myeloma. Eye (Lond). 2024;38:3416\u20137.","journal-title":"Eye (Lond)"},{"key":"1310_CR167","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1097\/ICB.0000000000001246","volume":"17","author":"A Taher","year":"2023","unstructured":"Taher A, Abadir E, McCluskey P, Hamad N, Lo TH, Heydon P. Presumptive recurrence of intraocular lymphoma despite chimeric antigen receptor t-cell therapy. Retin Cases Brief Rep. 2023;17:562\u20136.","journal-title":"Retin Cases Brief Rep"},{"key":"1310_CR168","first-page":"6","volume":"42","author":"A Takeda","year":"2025","unstructured":"Takeda A. Acute retinal necrosis and cytomegalovirus retinitis. J Eye. 2025;42:6 (in Japanese).","journal-title":"J Eye"},{"key":"1310_CR169","first-page":"9","volume":"66","author":"A Takeda","year":"2024","unstructured":"Takeda A. Vitreoretinal lymphoma. Ganka. 2024;66:9 (in Japanese).","journal-title":"Ganka"},{"key":"1310_CR170","first-page":"5","volume":"92","author":"A Takeda","year":"2021","unstructured":"Takeda A. Clinical features of primary central nervous system lymphoma involving the eye and secondary intraocular lymphoma. J Jpn Ophthalmol Assoc. 2021;92:5 (in Japanese).","journal-title":"J Jpn Ophthalmol Assoc"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01310-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-025-01310-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-025-01310-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:02:34Z","timestamp":1772172154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-025-01310-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":170,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1310"],"URL":"https:\/\/doi.org\/10.1007\/s10384-025-01310-3","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"18 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A. Takeda, research grants (Santen, HOYA, AMO, Chugai, Alcon), lecture fees (Santen, Kowa, Senju, Chugai, NIDEK, Novartis, AMO), Support for attending meetings and\/or travel (Kowa, AMO, Chugai, Santen, NIDEK); N. Yawata, research grants (Alcon, NIDEK, AMO, HOYA); K. Sonoda, research grants (Santen, Senju, HOYA, Wakamoto, AMO, Kowa, Alcon, Otsuka, Eisai, Senju, Sand), lecture fees (AMO, Novartis, Wakamoto, NIDEK, Canon, Topcon, Senju, Santen, Chugai, Bayer, Alcon, Eisai, Otsuka, Ono, Viatris, Celltrion Healthcare, Kowa), Support for attending meetings and\/or travel (Kowa, AMO, Chugai, Eisai, NIDEK, Santen, Senju).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}